Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acrivon TherapeuticsACRV -0.29%35 EV-to-OCF is 0.34 as of Aug. 13, 2026. GuruFocus rates ACRV with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 1,408 Biotechnology companies, Acrivon Therapeutics ranks worse than 74.93% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Acrivon Therapeutics's Enterprise Value is $-21.70 Mil.
Acrivon Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-64.67 Mil. Therefore, Acrivon Therapeutics's EV-to-OCF for today is 0.34.
The historical rank and industry rank for Acrivon Therapeutics's EV-to-OCF or its related term are showing as below:
ACRV'
s EV-to-OCF Range Over the Past 10 Years
Min: 0.32 Med: 0 Max: 0.35
Current: 0.34
During the past 6 years, the highest EV-to-OCF of Acrivon Therapeutics was 0.35. The lowest was 0.32. And the median was .
ACRV's EV-to-OCF is ranked worse than 74.93% of 1408
companies
in the Biotechnology industry
Industry Median: -3.53
vs ACRV: 0.34
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Acrivon Therapeutics's PE Ratio (TTM) for today is calculated as:
Acrivon Therapeutics's share price for today is $1.72.
Acrivon Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Acrivon Therapeutics EV-to-OCF Related Terms
Acrivon Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Acrivon Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Acrivon Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acrivon Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acrivon Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Acrivon Therapeutics's EV-to-OCF falls into.
Acrivon Therapeutics's current Enterprise Value is $-21.70 Mil.
Acrivon Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-64.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acrivon Therapeutics (ACRV) has a EV-to-OCF of 0.34 as of Aug. 13, 2026. Over the past decade, Acrivon Therapeutics' EV-to-OCF has ranged from 0.32 to 0.35. According to the industry distribution chart, Acrivon Therapeutics ranks #1055 out of 1408 companies in the Biotechnology industry, placing it in the top 74.9%.
Is Acrivon Therapeutics' EV-to-OCF too high?
Acrivon Therapeutics' current EV-to-OCF is 0.34. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 0.35. Based on the distribution chart, Acrivon Therapeutics ranks #1055 out of 1408 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Acrivon Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Acrivon Therapeutics' EV-to-OCF compare to SPRO and BSEM?
According to the Biotechnology industry distribution chart, Acrivon Therapeutics ranks #1055 out of 1408 companies for EV-to-OCF. This places Acrivon Therapeutics in the lower half of its industry. Historically, Acrivon Therapeutics' own EV-to-OCF has ranged from 0.32 to 0.35 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Acrivon Therapeutics's current EV-to-OCF is 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrivon Therapeutics stock overvalued right now?
Acrivon Therapeutics (ACRV) has a current EV-to-OCF of 0.34. The current EV-to-OCF is 0.34. Acrivon Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Acrivon Therapeutics (ACRV), the current EV-to-OCF is 0.34 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
35GF Score
Get the complete analysis for ACRV
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACRV has been successfully added to your 
